生化复发前列腺癌的无转移生存期与无治疗生存期：EMBARK 试验。

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2024-08-20 Epub Date: 2024-05-16 DOI:10.1200/JCO.24.00279

David J Einstein, Meredith M Regan, Julia S Stevens, David F McDermott, Ravi A Madan

引用次数: 0

摘要

什么对 BCR 前列腺癌患者最重要？无转移生存期与无治疗生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.

What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.